Suchergebnisse - "You, Xiangyun"

PubPharm (5)

1

Corrigendum to "Emerging strategy for the treatment of urothelial carcinoma : Advances in antibody-drug conjugates combination therapy" Biomed. Pharmacother. 171 (2024) 116152

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2024

von You, X. | Zhu, C. | Yu, P. | +5

ErratumFor: Biomed Pharmacother. 2024 Feb;171:116152. - PMID 38228034

2

Emerging strategy for the treatment of urothelial carcinoma : Advances in antibody-drug conjugates combination therapy

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2024

von You, X. | Zhu, C. | Yu, P. | +5

ErratumIn: Biomed Pharmacother. 2024 Mar 14;:116430. - PMID 38485617

3

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance : A systematic review

enthalten in: Frontiers in endocrinology | 2022

von You, X. | Huang, S. | Wang, X. | +5

4

Renal cell carcinoma of different pathological types in bilateral native kidneys of a kidney transplant recipient : A case report and literature review

enthalten in: Frontiers in oncology | 2022

von Yi, C. | You, X. | Sha, A. | +4

5

Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death

enthalten in: Cell death & disease | 2021

von Xiang, Z. | Sun, Y. | You, B. | +6

1
[1]